CytRx publishes results from Arimoclomol Phase 2 trial for sIBM
Category: #health  By Saipriya Iyer  Date: 2020-02-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

CytRx publishes results from Arimoclomol Phase 2 trial for sIBM

CytRx Corporation, a biopharmaceutical firm that specializes principally in neurodegenerative and oncology diseases, recently announced its data from Orphazyme double-blinded Phase 2 study of arimoclomol for the treatment of sIBM (Sporadic Inclusion Body Myositis).

Reportedly, the study was a 24-patient randomized pilot (with 8 patients on placebo and 16 on arimoclomol) where almost 83% of patients receiving treatment from arimoclomol were stabilized whereas 25% managed to be stabilized in placebo.

Orphazyme trial is expected to be completed by the end of 2020, with interim analysis coming in the first half of 2020. Moreover, the results from this study are slated to be revealed by the first half of 2021, with regulatory submission being submitted by the second half of 2021.

Speaking on the move, Eric Curtis, President and Chief Operating Officer, CytRx, said that the company is with the findings of Phase 2 clinical study treating sIBM with arimoclomol. Moreover, it is projected that there are nearly 40,000 patients in Europe and the USA who go through this debilitating disease and presently there are no effective therapies for this massive population of sIBM patients.

Incidentally, CytRx has also announced that Orphazyme A/S licensed arimoclomol has completed a major new capital raise of around $110 million for expansion. Orphazyme claims that the funding will support the finalization of arimoclomol's clinical advancements in sIBM and help prepare regulatory filings in Europe and possibly in the U.S.

The investment also offers noteworthy cash for Orphazyme to further arimoclomol towards commercialization in NPC. Orphazyme also aims at using the proceeds to cover the completion of clinical development of arimoclomol in ALS.

Reports claim that CytRx is eligible to receive over $120 million in future milestones, along with royalties, from the company’s arimoclomol licensing deal. If received, the investment would secure a minimum of $250 million in net operating losses.

Source Credit: https://cytrxcorporation.gcs-web.com/news-releases/news-release-details/cytrx-corporation-highlights-recently-published-data-its?field_nir_news_date_value%5Bmin%5D=2017&items_per_page=10#views-exposed-form-widget-news-widget-news-ul



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
By Saipriya Iyer

Copper3D, a Chile- and U.S.-based antibacterial solutions provider, has recently worked on a project to create an antibacterial 3D printed device to mitigate the risk of HIV transmission during breastfeeding. The compa...

Tetra commences PoC clinical trial of PPP003v for companion dogs
Tetra commences PoC clinical trial of PPP003v for companion dogs
By Saipriya Iyer

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in ...

Satipharm begins clinical trial of CBD capsules for treating menopause
Satipharm begins clinical trial of CBD capsules for treating menopause
By Saipriya Iyer

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting adv...